Abionyx Pharma SA

Abionyx Pharma SA is a new-generation biotechnology company focused on discovering and developing innovative therapies for patients lacking effective treatments, particularly in renal and ophthalmological diseases. It specializes in HDL (High Density Lipoprotein) therapies, leveraging advanced lipoprotein particles to address unmet medical needs. Key drug candidates include CER-001, a recombinant apoA-I based HDL mimetic designed to replicate pre-beta HDL properties for treating post-acute coronary syndrome and familial hypoalphalipoproteinemia; CER-002, a peroxisome proliferator-activated receptor delta agonist targeting cardiovascular and metabolic disorders; and CER-209, aimed at metabolic liver diseases, atherosclerosis, and non-alcoholic steatohepatitis (NASH). Formerly known as Cerenis Therapeutics Holding SA, the company rebranded in August 2019. Founded in 2005 and headquartered in Balma, France, Abionyx Pharma SA collaborates with research, medical, and biopharmaceutical partners to advance targeted drug delivery using novel HDL vectors, contributing significantly to the biotech sector's efforts in cardiovascular, metabolic, and rare disease innovation.